RxDoctor Payments DataLook up a doctor →

Andrew Behunin, DO

Cardiovascular Disease · Draper, UTNPI 1356634869

Payments from drug & device makers

$191,852in general payments, 2019–2025

Across 997 payments — averaging $192.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$175K
  • Abbott$4K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Heartflow, Inc.$1K
  • Edwards Lifesciences$1K
  • Philips North America LLC$1K
  • plus $7K from 33 others

What the payments were for

  • Consulting fees$880%
  • Speaking & faculty fees$151,93879%
  • Travel & lodging$20,49611%
  • Food & beverage$19,29410%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$191,852 in reported general payments places this provider in the 90th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$237,298
Medicare patients
1,726
Services billed
3,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban295$327,591
EntrestoSacubitril/Valsartan33$43,568
XareltoRivaroxaban34$42,800
Repatha SureclickEvolocumab54$40,640
FarxigaDapagliflozin Propanediol28$26,109
BrilintaTicagrelor26$24,665
Atorvastatin Calcium467$3,411
Metoprolol Succinate251$2,442
Rosuvastatin Calcium221$2,174
Diltiazem 24hr Er (Cd)Diltiazem Hcl62$1,921
Losartan Potassium246$1,834
Carvedilol299$1,749
Potassium Chloride74$1,690
Flecainide Acetate57$1,640
Valsartan25$1,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,044$327,591295 claims
AstraZenecaFarxiga, Brilinta$248$50,77454 claims
NovartisEntresto$1,259$43,56833 claims
Johnson & JohnsonXarelto$669$42,80034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 131 cardiovascular disease providers in Utah.

Other cardiovascular disease in Draper

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →